Office of Rep. Heo Jongsik: 47 reports, including 9 involving anticancer injections
MFDS classifies 64% as "No Action Required"

Pharmaceutical companies reported 47 cases of drug supply suspensions or shortages in the first half of this year alone, citing reasons including worsening profitability and weak sales. This is the highest number for a half-year period since 2021. The drugs whose supply was suspended include essential treatments such as anticancer drugs and emergency treatments for epilepsy, prompting calls for the government to take proactive measures.


"Due to Poor Profitability and Weak Sales"... Drug Supply Suspensions Hit H1 Record View original image

According to data submitted by the Ministry of Food and Drug Safety to Heo Jong-sik, a lawmaker from the Democratic Party of Korea who serves on the National Assembly's Health and Welfare Committee, 47 of the 135 reports of drug supply suspensions or shortages received between January and June were attributed to economic reasons. Of those, 20 cited profitability issues and 27 cited weak sales.


This was a 56.7% increase from the 30 cases reported in the first half of last year. It represented 82.5% of the 57 reports of supply suspensions or shortages attributed to economic reasons for all of last year.


The share of reports of drug supply suspensions or shortages attributed to economic reasons also rose. It was 21.6% in the first half of last year, but climbed by 13.2 percentage points to 34.8% in the first half of this year. The figures were 19.3% in the first half of 2024, 23.2% in the second half of 2024, 21.6% in the first half of 2025, and 13.6% in the second half of 2025. This indicates that supply disruptions due to economic reasons have become more pronounced this year.


The drugs whose supply was suspended included medicines needed to treat patients, such as anticancer drugs and emergency treatments. In the first half of this year, nine anticancer injections were reported to have supply suspensions or shortages for economic reasons. Two reports each involved dacarbazine (DTI Injection) and cisplatin (Unistin Injection), while the list also included vinblastine (Velbastin Injection), daunorubicin (Daunosin Injection), mitoxantrone (Mitron Injection), vincristine (Vincrin Injection), and fulvestrant (Faslodex Injection). Among these, the manufacturers of dacarbazine and vinblastine said in May that they would resume supply.


Supply suspensions were also reported for nervous system drugs. The Ministry of Food and Drug Safety is monitoring Cerebyx Injection, a fosphenytoin injection used for emergency treatment of status epilepticus, after a supply suspension was reported due to weak sales. Two reports involving diazepam tablets, a tranquilizer, cited profitability issues, but no separate measures were taken because alternative drugs were available. In addition, supply suspensions were reported due to weak sales for peritoneal dialysis solution used to treat patients with kidney failure (three types of Peripure) and Cervarix Prefilled Syringe, a cervical cancer vaccine included in the national immunization program.


Of the 47 cases reported for economic reasons in the first half of this year, the Ministry of Food and Drug Safety classified 30 (63.8%) as requiring no action, citing factors such as the availability in Korea of alternative drugs with the same ingredients or effects. Seven drugs are being monitored, eight are under review, and measures for made-to-order manufacturing were taken in only two cases.



“Cases in which essential treatments such as anticancer injections are discontinued due to profitability issues and weak sales have increased significantly,” Heo said. “Even pharmaceutical companies that produce alternative drugs may abandon production at any time if their profitability worsens, leaving medical professionals and patients facing continued uncertainty.” He added, “For drugs whose supply has been suspended, the government should assess the actual capacity to supply the market rather than simply checking whether alternatives exist. The government must urgently establish a system for intervening early, including by adjusting drug prices to reflect costs and expanding made-to-order manufacturing of essential medicines with low profitability.”


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing